Cetuximab biosimilar (AlphaMab)

西妥昔单抗生物类似药（康宁杰瑞）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCetuximab biosimilar (AlphaMab)
Drug Alias Name西妥昔单抗生物仿制药（康宁杰瑞）KN-005
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsUrinary Bladder NeoplasmsHead and Neck NeoplasmsAnus Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSuzhou Alphamab Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Alphamab Co Ltd
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsHead and Neck NeoplasmsAnus Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC06
Related LinksN/A